Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy

Gemfibrozil therapy alone can induce severe myopathy and rhabdomyolysis. This catastrophic complication had been frequently reported in renal failure patients. Dosage reduction is therefore compulsory in patients with compromised renal function, no matter which type of renal replacement therapy they receive. This study's patient clearly demonstrates that gemfibrozil can induce severe rhabdomyolysis, even in patients receiving CVVH, if the dosage is not properly adjusted.